Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373693" target="_blank" >RIV/00216208:11130/17:10373693 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/17:10373693

Result on the web

<a href="https://doi.org/10.1007/s12032-017-1035-x" target="_blank" >https://doi.org/10.1007/s12032-017-1035-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12032-017-1035-x" target="_blank" >10.1007/s12032-017-1035-x</a>

Result language

angličtina

Original language name

Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients

Original language description

Personalized peptide vaccination is a promising immunotherapeutic approach in prostate cancer (PCa). We therefore examined whether an approach, utilizing personalized multiple peptide-mediated ex vivo enrichment with effector T cells reactive to multiple tumor-associated antigens (TAAs), could be employed as a basis for the development of T cell immunotherapy of PCa. In this study, we used the non-adherent fraction (lymphocytes) of cryopreserved peripheral blood mononuclear cells from a leukapheretic product of biochemically recurrent (BR, n = 14) and metastatic hormone-refractory (HR, n = 12) PCa patients. The lymphocytes were primed with a pool of mixed overlapping peptides derived from 6 PCa TAAsPSA, PAP, NY-ESO-1, MAGE-A1, MAGE-A3 and MAGE-A4. After 2 weeks of culture, the cells were stimulated with the peptides and T cell reactivity determined by externalization of CD107a. No TAAs-reactive effector T cells were detected in the patient&apos;s lymphocytes after their reconstitution. However, following their priming with the TAAs-derived peptides and 2-week culturing, the lymphocytes became enriched with polyclonal TAAs-reactive effector CD8(+) T cells in 8 out of 14 BR and 5 out of 12 HR patients. No such reactive CD8(+) T cells were detected in cultured lymphocytes without the peptide priming. Stimulation of the responding cultures with peptides derived from individual TAAs revealed a unique repertoire of the reactive CD8(+) T cells. Our strategy revealed that the personalized multiple peptide-mediated ex vivo enrichment with multiple TAAs-reactive T cells in the PCa patient&apos;s lymphocytes is a viable approach for development of T cell immunotherapy of PCa.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30102 - Immunology

Project

<a href="/en/project/NV16-28135A" target="_blank" >NV16-28135A: Preparation of polyclonal cancer-specific T-cells for adoptive cellular immunotherapy of prostate cancer</a><br>

Continuities

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Medical Oncology

ISSN

1357-0560

e-ISSN

—

Volume of the periodical

34

Issue of the periodical within the volume

10

Country of publishing house

US - UNITED STATES

Number of pages

13

Pages from-to

—

UT code for WoS article

000411872900008

EID of the result in the Scopus database

2-s2.0-85028701567